Results 151 to 160 of about 3,096 (189)

Balancing effectiveness, toxicity, and individualization: enfortumab vedotin in advanced urothelial cancer. [PDF]

Transl Androl Urol
Wang N, Tully KH.
europepmc   +1 more source

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2^EV project. [PDF]

Clin Exp Med
Rizzo A, Myint ZW, Ciccimarra F, Zgura A, Matrana MR, Büttner T, Kopecky J, Vida AR, Rizzo M, Fujita K, Brunetti O, Santini D, Park SH, Formisano L, Poprach A, Kucharz J, Comes MC, Bove S, Fanizzi A, Massafra R, Cazzato G, Monteiro FSM, Mollica V, Massari F, Cerrillo JM, Santoni M.   +25 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Enfortumab-vedotin

Reactions Weekly
  +17 more sources

Benefit with enfortumab vedotin confirmed

Nature Reviews Clinical Oncology, 2021
openaire   +4 more sources

Enfortumab-vedotin

Reactions Weekly, 2022
  +7 more sources

Enfortumab vedotin

Reactions Weekly, 2021
  +4 more sources

Enfortumab Vedotin (Padcev)

Canadian Journal of Health Technologies
The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) recommends that public drug programs reimburse Padcev, in combination with pembrolizumab, for treating patients with locally advanced urothelial cancer (UC) or metastatic urothelial cancer (mUC).
openaire   +1 more source

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

New England Journal of Medicine, 2022
Sharon M Castellino
exaly